In a report published on Wednesday, Jefferies analyst Thomas Wei initiated coverage on Lexicon Pharmaceuticals LXRX with a Buy Rating and a price target of $3.50.
In the report, Jefferies stated, "We believe investors have underestimated the potential for SGLTs to show a CV outcomes benefit. We see an LX4211 pharma deal as a potential near-term catalyst prior to Phase 3 trials."
Lexicon Pharmaceuticals closed on Wednesday at $2.22.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in